Ted Love, Global Blood Therapeutics CEO
August 8, 2022 07:34 AM EDTUpdated September 7, 06:43 PM
Deals

Up­dat­ed: Pfiz­er scoops up Glob­al Blood Ther­a­peu­tics and its sick­le cell ther­a­pies for $5.4B

Amber Tong

Pfiz­er is drop­ping $5.4 bil­lion to ac­quire Glob­al Blood Ther­a­peu­tics.

Just ahead of the week­end, word got out that Pfiz­er was close to clinch­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease med­i­cine: ‘We need to sit down with Elon Musk’

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves

Can Bill An­der­son save Bay­er?

Phar­ma-backed Mis­sion Ther­a­peu­tics stops pre­clin­i­cal op­er­a­tions, fo­cus­es on two clin­i­cal as­sets

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times